Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma.

Regelink JC, Raijmakers PG, Bravenboer N, Milek R, Hoetjes NJ, de Kreuk AM, van Duin M, Wondergem MJ, Lips P, Sonneveld P, Zijlstra JM, Zweegman S.

EJNMMI Res. 2016 Dec;6(1):46. doi: 10.1186/s13550-016-0197-4. Epub 2016 May 31.

2.

Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.

Kramer GM, Frings V, Hoetjes N, Hoekstra OS, Smit EF, de Langen AJ, Boellaard R.

J Nucl Med. 2016 Sep;57(9):1343-9. doi: 10.2967/jnumed.115.170225. Epub 2016 Apr 21.

3.

18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.

Wondergem MJ, Rizvi SN, Jauw Y, Hoekstra OS, Hoetjes N, van de Ven PM, Boellaard R, Chamuleau ME, Cillessen SA, Regelink JC, Zweegman S, Zijlstra JM.

J Nucl Med. 2015 Feb;56(2):216-21. doi: 10.2967/jnumed.114.149625. Epub 2015 Jan 15.

4.

Detection of subclinical synovitis with macrophage targeting and positron emission tomography in patients with rheumatoid arthritis without clinical arthritis.

Gent YY, Ahmadi N, Voskuyl AE, Hoetjes N, van Kuijk C, Britsemmer K, Turkstra F, Boers M, Hoekstra OS, van der Laken CJ.

J Rheumatol. 2014 Nov;41(11):2145-52. doi: 10.3899/jrheum.140059. Epub 2014 Oct 1.

PMID:
25274888
5.

The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects.

Tolboom N, Berendse HW, Leysen JE, Yaqub M, van Berckel BN, Schuit RC, Ponsen MM, Bakker E, Hoetjes NJ, Windhorst AD, Carlsson ML, Lammertsma AA, Carlsson A.

Neuropsychopharmacology. 2015 Jan;40(2):472-9. doi: 10.1038/npp.2014.195. Epub 2014 Aug 5.

6.

18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair.

Wondergem MJ, Herrmann K, Syrbu S, Zijlstra JM, Hoetjes N, Hoekstra OS, Cillessen SA, Moesbergen LM, Buck AK, Vose JM, Juweid ME.

EJNMMI Res. 2014 Jan 8;4(1):3. doi: 10.1186/2191-219X-4-3.

7.

Cerebral blood flow and glucose metabolism measured with positron emission tomography are decreased in human type 1 diabetes.

van Golen LW, Huisman MC, Ijzerman RG, Hoetjes NJ, Schwarte LA, Lammertsma AA, Diamant M.

Diabetes. 2013 Aug;62(8):2898-904. doi: 10.2337/db12-1159. Epub 2013 Mar 25.

8.

Cerebral blood flow and glucose metabolism in healthy volunteers measured using a high-resolution PET scanner.

Huisman MC, van Golen LW, Hoetjes NJ, Greuter HN, Schober P, Ijzerman RG, Diamant M, Lammertsma AA.

EJNMMI Res. 2012 Nov 20;2(1):63. doi: 10.1186/2191-219X-2-63.

9.

In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography.

te Beek ET, de Boer P, Moerland M, Schmidt ME, Hoetjes NJ, Windhorst AD, van Berckel BN, Cohen AF, van Gerven JM, Lammertsma AA.

J Psychopharmacol. 2012 Aug;26(8):1128-35. doi: 10.1177/0269881111435251. Epub 2012 Jan 30.

PMID:
22290934
10.

Blood-brain barrier P-glycoprotein function in Alzheimer's disease.

van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, Comans EF, Hoetjes NJ, Tolboom N, Langer O, Müller M, Scheltens P, Lammertsma AA, van Berckel BN.

Brain. 2012 Jan;135(Pt 1):181-9. doi: 10.1093/brain/awr298. Epub 2011 Nov 26.

PMID:
22120145
11.

Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis.

Cheebsumon P, Velasquez LM, Hoekstra CJ, Hayes W, Kloet RW, Hoetjes NJ, Smit EF, Hoekstra OS, Lammertsma AA, Boellaard R.

Eur J Nucl Med Mol Imaging. 2011 May;38(5):832-42. doi: 10.1007/s00259-010-1705-9. Epub 2011 Jan 6.

12.

Partial volume correction strategies for quantitative FDG PET in oncology.

Hoetjes NJ, van Velden FH, Hoekstra OS, Hoekstra CJ, Krak NC, Lammertsma AA, Boellaard R.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1679-87. doi: 10.1007/s00259-010-1472-7. Epub 2010 Apr 27.

13.

Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.

Nogová L, Boellaard R, Kobe C, Hoetjes N, Zander T, Gross SH, Dimitrijevic S, Pellas T, Eschner W, Schmidt K, Bangard C, Hayes W, Thomas RK, Dietlein M, Giaccone G, Hoekstra OS, Lammertsma AA, Wolf J.

J Nucl Med. 2009 Nov;50(11):1815-9. doi: 10.2967/jnumed.109.065367. Epub 2009 Oct 16.

Supplemental Content

Loading ...
Support Center